<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72147">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01846442</url>
  </required_header>
  <id_info>
    <org_study_id>ERC-210</org_study_id>
    <nct_id>NCT01846442</nct_id>
  </id_info>
  <brief_title>Topical DHEA Against Vaginal Atrophy</brief_title>
  <official_title>Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EndoCeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EndoCeutics Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the dose-response of vaginal mucosa parameters to
      the local action of DHEA in postmenopausal women suffering from vaginal atrophy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Co-primary endpoint: change from baseline over time of vaginal cell maturation (percentage of parabasal and superficial cells; maturation value)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary endpoint: change from baseline over time of vaginal pH.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-primary endpoint: change from baseline over time in the moderate to severe symptom of vaginal atrophy identified by the subject as most bothersome to her.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tolerance to intravaginal administration of DHEA.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over time in quality of life evaluated by the Menopause Specific Quality of Life (MENQOL) questionnaire.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline over time in sexual function evaluated by the Abbreviated Sexual Function (ASF), the Sexual Concern (SC) and the Psychological General Well-Being (PGWB) questionnaires.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25% DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5% DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0% DHEA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Prasterone, Dehydroepiandrosterone, Vaginorm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA (0.25%)</intervention_name>
    <description>Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.</description>
    <arm_group_label>0.25% DHEA</arm_group_label>
    <other_name>Prasterone, Dehydroepiandrosterone, Vaginorm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA (0.5%)</intervention_name>
    <description>Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.</description>
    <arm_group_label>0.5% DHEA</arm_group_label>
    <other_name>Prasterone, Dehydroepiandrosterone, Vaginorm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA (1.0%)</intervention_name>
    <description>Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.</description>
    <arm_group_label>1.0% DHEA</arm_group_label>
    <other_name>Prasterone, Dehydroepiandrosterone, Vaginorm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal women (non hysterectomized or hysterectomized)

          -  Women between 40 and 75 years of age

          -  Willing to participate in the study and sign an informed consent

          -  Women having a low maturation index (no greater part of guidance than 5% of
             superficial cells on vaginal smear)

          -  Women having a vaginal pH above 5

          -  Women who have self-identified at least one moderate to severe symptoms of
             vulvovaginal atrophy

        Exclusion Criteria:

          -  Undiagnosed abnormal genital bleeding

          -  Hypertension equal to or above 160/95 mm Hg or not controlled by standard therapy

          -  The administration of any investigational drug within 30 days of screening visit

          -  Endometrial hyperplasia at biopsy performed at screening or endometrial cancer

          -  Use of estrogens/progestins products (vaginal, oral, pellet, transdermal, etc) in the
             4 weeks to 6 months (depending on the product used) prior study entry
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David F Archer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center, Eastern Virginia Medical Scholl, Norfolk, VA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EndoCeutics site # 05</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EndoCeutics site # 03</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EndoCeutics site # 10</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EndoCeutics site # 09</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EndoCeutics site # 08</name>
      <address>
        <city>Shawinigan</city>
        <state>Quebec</state>
        <zip>G9N 2H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EndoCeutics site # 11</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EndoCeutics site # 02</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EndoCeutics site # 01</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol. 2008 Sep;111(3-5):178-94. Epub 2008 Jun 12. Erratum in: J Steroid Biochem Mol Biol. 2008 Nov;112(1-3):169.</citation>
    <PMID>18598765</PMID>
  </reference>
  <reference>
    <citation>Labrie F. DHEA, important source of sex steroids in men and even more in women. Prog Brain Res. 2010;182:97-148. doi: 10.1016/S0079-6123(10)82004-7.</citation>
    <PMID>20541662</PMID>
  </reference>
  <results_reference>
    <citation>Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Bérubé R, Bélanger P, Berger L, Gilbert L, Martel C, Balser J. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause. 2009 Sep-Oct;16(5):897-906.</citation>
    <PMID>19436226</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009 Sep-Oct;16(5):907-22.</citation>
    <PMID>19436225</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009 Sep-Oct;16(5):923-31.</citation>
    <PMID>19424093</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Martel C, Balser J. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol. 2010 Jul;26(7):524-32. doi: 10.3109/09513590903511547.</citation>
    <PMID>20459349</PMID>
  </results_reference>
  <results_reference>
    <citation>Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011 Apr;14(2):282-8. doi: 10.3109/13697137.2010.535226. Epub 2011 Jan 18.</citation>
    <PMID>21244215</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvar/vaginal atrophy</keyword>
  <keyword>Atrophic Vaginitis</keyword>
  <keyword>Dehydroepiandrosterone</keyword>
  <keyword>DHEA</keyword>
  <keyword>Prasterone</keyword>
  <keyword>Vaginorm</keyword>
  <keyword>Menopause</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
